Navigation Links
UT Southwestern investigating hypothermic technique in treating pediatric head injuries
Date:10/3/2007

DALLAS Oct. 3, 2007 UT Southwestern Medical Center has been selected to take part in an $11.5 million multicenter clinical trial that is examining the effectiveness of induced hypothermia as a therapy for brain swelling in children who have suffered severe traumatic brain injuries.

The 12 centers that are participating in the trial are expected to enroll a total of 340 children up to age 16 in the five-year trial, which is being funded by the National Institute of Neurological Disorders and Stroke, a component of the National Institutes of Health. Childrens Medical Center Dallas, which has a Level I pediatric trauma center, will serve as the local coordinating site. The study is being led by Childrens Hospital of Pittsburgh.

Pediatric patients who are eligible for the trial must have severe brain injury caused by blunt trauma. This excludes patients who have suffered injuries that penetrate the skull such as gunshot wounds.

Those patients selected to receive hypothermia therapy will be cooled to between 32 and 33 degrees Celsius (89 to 90 degrees Fahrenheit), using special cooling blankets and/or cooled saline given intravenously. In addition to normal emergency care, they will remain cooled for 48 hours while being closely monitored in the intensive care unit. Children will be tracked by researchers for one year to record outcomes, with a battery of tests being conducted at six and 12 months following the injury.

Trauma is the leading cause of death and disability in children, more than all other causes combined, said Dr. Pam Okada, associate professor of pediatrics at UT Southwestern and lead investigator of the Dallas trial. Previous studies have shown hypothermia is not only safe in children following severe traumatic brain injury, but may improve their chance of survival.

It had been thought that children had better outcomes than adults following traumatic brain injury, Dr. Okada said. In fact, it has been demonstrated that younger children (those younger than 4) actually have worse outcomes. Problems that develop with motor, behavior, learning, memory and other higher-level functions are common even in children with only moderate or mild concussions or injuries, she said.

In head injuries where the skull remains intact there is little room for swelling, Dr. Okada said. This causes diminished blood flow resulting in brain damage. Cooling the body may reduce the swelling and possibly prevent continuing damage. If this therapy proves effective, it would be a major breakthrough in the treatment of traumatic brain injuries.

According to federal and state laws, those who participate in a clinical research study must provide or, in the case of a child, have a guardian provide informed consent. Because of the nature of this trial and the fact that hypothermia must be induced within six hours of injury, it may be sometimes impossible to obtain consent at the time of brain injury.

For this reason, researchers are notifying the public that informed consent will be waived. Every attempt to contact family members to provide notification and obtain consent for continued participation will be made as soon as possible after enrollment.


'/>"/>

Contact: Erin Prather Stafford
erin.pratherstafford@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. WHO Officials Investigating Eight Suspected Bird Flu Cases
2. Investigating Alternatives for Childhood Depression
3. Health Officials Investigating Plausible Chikungunya Outbreak in Bengal villages
4. Investigating Coral Reefs to Help Understand Past and Future Climate Change
5. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
6. New Laser Techniques cure degeneration of the eye
7. Conventional pap smears techniques to detect cervical cancer are here to stay
8. Micro-camera provides new breast imaging technique
9. IVF technique May Increase The Risk Of Birth Defects
10. New technique to diagnose heart disease
11. Novel biopsy technique for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... OF PRUSSIA, PA and LONDON, UK (PRWEB) , ... May 06, ... ... to earn accolades for his success in changing the way the pharmaceutical industry conducts ... 100 list of the world’s most influential people in pharma, and he was honored ...
(Date:5/6/2016)... ... 06, 2016 , ... US Sports Camps has collaborated with State Rugby Organization ... University this summer. Employing world-class rugby figures, including former Team USA players and college ... on key fundamentals, match play, fitness and more. , “US Sports Camps is honored ...
(Date:5/6/2016)... ... May 06, 2016 , ... Innovations ... upcoming episode, airing third quarter 2016, via Discovery Channel. Dates and show times ... leader in optimized drug discovery through innovative cellular analysis. In this segment, viewers ...
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a range ... game for traditional brokers and health plans. “ The Rapid Emergence of Online Benefits ... Atlantic Information Services, Inc. (AIS), will offer an accurate picture of online benefits today, ...
(Date:5/6/2016)... ... 06, 2016 , ... Canadian author Mark Black is a speaker, author, and life ... around the world … with the help of his publisher Strategic Book Group and its ... in a hospital bed waiting for a miracle: He needed a heart and double-lung transplant. ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Systemic Lupus Erythematosus ...  report to their offering.       ... The latest research Europe Systemic Lupus Erythematosus ... provides comprehensive insights into Systemic Lupus Erythematosus ...
(Date:5/4/2016)... COUNTY, Calif. , May 4, 2016  It,s time for an upgrade. There ... shown on a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled ... brands as well as a world class manufacturer of innovative technology.  Photo ... ... ...
(Date:5/4/2016)... , May 4, 2016 ... Jerusalem announced today that it had signed an ... Inc. , developer of novel protein degradation and immunomodulatory ... and commercialization of drug candidates representing first-in-class therapy for ... were not disclosed. The novel technology was ...
Breaking Medicine Technology: